Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Published version of a preprint
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
PI3K-targeting therapy represents one of the most sought-after therapies for glioblastoma (GBM). Several small-molecule inhibitors have been evaluated in clinical trials, however, the emergence of resistance limits treatment potential. Here, we generated a patient-derived glioma sphere-forming cell (GSC) xenograft model resistant to the PI3K-specific inhibitor BKM-120. Integrated RNA sequencing and high-throughput drug screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kinase 1 (CDK1) signaling pathway was the main driver of PI3K inhibitor resistance in the resistant xenografts. Aurora kinase was upregulated and pCDK1 was downregulated in resistant tumors from both xenografts and tumor tissues from patients treated with the PI3K inhibitor. Mechanistically, the tyrosine kinase receptor Tie2 physically interacted with FGFR1, promoting STAT3 phosphorylation and binding to the AURKA promoter, which increased Aurora A expression in resistant GSCs. Concurrent inhibition of Aurora A and PI3K signaling overcame PI3K inhibitor-induced resistance. This study offers a proof of concept to target PI3K and the collateral-activated pathway to improve GBM therapy. SIGNIFICANCE: These findings provide novel insights into the mechanisms of PI3K inhibitor resistance in glioblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PLK1 signaling has also been reported to confer resistance to PI3K inhibitors by Tie-FGFR1-STAT3 [41].”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [41]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, Ø., Gjertsen, B. T., & Nolan, G. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.028 · Cited by 684
Cited by
Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions
Hashemi, M., Etemad, S., Rezaei, S., Ziaolhagh, S., Rajabi, R., Rahmanian, P., Abdi, S., Koohpar, Z. K., Rafiei, R., Raei, B., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114204 · Cited by 167
Emerging roles of Aurora-A kinase in cancer therapy resistance
Zheng, D., Li, J., Yan, H., Zhang, G., Li, W., Chu, E., & Wei, N. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.013 · Cited by 128
Inverso, D., Shi, J., Lee, K. H., Jakab, M., Ben-Moshe, S., Kulkarni, S. R., Schneider, M., Wang, G., Komeili, M., Vélez, P. A., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.05.001 · Cited by 114
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02077-w · Cited by 70
“PLK1 signaling has also been reported to confer resistance to PI3K inhibitors by Tie-FGFR1-STAT3 [41].”
BackgroundThe multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 63
Self-citation
Metadata
- Authors
- Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., Ligon, K. L., Yung, W. K. A., & Koul, D.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- 1Brain Tumor Center, Departments of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Texas A&M University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Koul, Dimpy
- ORCID
- Venue
- Cancer Research
- Published
- 2019-10-01
- Volume
- 79
- Issue
- 19
- Pages
- 5088-5101
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2968054305
- Cited by
- 27
- References
- 40
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The National Brain Tumor Society
- The National Foundation for Cancer Research
- SPORE (P50CA127001)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
- Keywords
- glioblastoma, PI3K inhibitor resistance, Tie2, FGFR1, AURKA, PLK1, CDK1, STAT3 phosphorylation, glioma stem cells, drug resistance, combination therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Glioblastoma, Humans, Male, Mice, Nude, Proto-Oncogene Proteins, Signal Transduction, Up-Regulation, CDC2 Protein Kinase, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor, TIE-2, Protein Kinase Inhibitors, Mice, Receptor, Fibroblast Growth Factor, Type 1, Aurora Kinase A, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-0325
- The paper
- Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., Ligon, K. L., Yung, W. K. A., & Koul, D. (2019). Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-0325
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.